Journey Medical Co. (NASDAQ:DERM) Short Interest Up 6.5% in January

Journey Medical Co. (NASDAQ:DERM - Get Free Report) was the recipient of a large increase in short interest during the month of January. As of January 31st, there was short interest totalling 83,800 shares, an increase of 6.5% from the January 15th total of 78,700 shares. Approximately 0.8% of the shares of the stock are short sold. Based on an average daily trading volume, of 80,800 shares, the days-to-cover ratio is currently 1.0 days.

Institutional Investors Weigh In On Journey Medical

A number of large investors have recently bought and sold shares of the stock. Cetera Investment Advisers grew its holdings in Journey Medical by 21.8% during the 4th quarter. Cetera Investment Advisers now owns 13,839 shares of the company's stock valued at $54,000 after buying an additional 2,478 shares during the last quarter. PVG Asset Management Corp boosted its holdings in shares of Journey Medical by 5.7% during the third quarter. PVG Asset Management Corp now owns 167,545 shares of the company's stock worth $947,000 after purchasing an additional 9,005 shares during the last quarter. Nwam LLC purchased a new stake in shares of Journey Medical in the third quarter valued at $59,000. Kovitz Investment Group Partners LLC purchased a new stake in shares of Journey Medical in the third quarter valued at $66,000. Finally, Geode Capital Management LLC grew its position in shares of Journey Medical by 13.5% in the third quarter. Geode Capital Management LLC now owns 108,435 shares of the company's stock valued at $613,000 after purchasing an additional 12,882 shares during the period. Institutional investors and hedge funds own 7.25% of the company's stock.

Journey Medical Price Performance

NASDAQ:DERM traded up $0.05 during trading hours on Friday, reaching $5.19. 20,844 shares of the company traded hands, compared to its average volume of 55,942. The firm's 50-day moving average is $4.43 and its 200-day moving average is $5.04. The stock has a market cap of $108.42 million, a P/E ratio of -5.52 and a beta of 1.03. The company has a debt-to-equity ratio of 1.81, a current ratio of 1.38 and a quick ratio of 1.03. Journey Medical has a 1-year low of $2.85 and a 1-year high of $6.89.

About Journey Medical

Journey Medical Corporation focuses on the development and commercialization of pharmaceutical products for the treatment of dermatological conditions in the United States. The company's marketed products include Qbrexza, a medicated cloth towelette for the treatment of primary axillary hyperhidrosis; Accutane, an oral isotretinoin drug to treat severe recalcitrant nodular acne; and Amzeeq, a topical formulation of minocycline for the treatment of inflammatory lesions of non-nodular moderate to severe acne vulgaris.